Published in Cancer Immunol Immunother on February 06, 2010
The androgen receptor: a biologically relevant vaccine target for the treatment of prostate cancer. Cancer Immunol Immunother (2012) 1.50
DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer. J Immunother (2010) 1.12
Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockade. J Immunol (2012) 1.09
Vaccines targeting the cancer-testis antigen SSX-2 elicit HLA-A2 epitope-specific cytolytic T cells. J Immunother (2011) 0.97
Immunotherapy for prostate cancer: lessons from responses to tumor-associated antigens. Front Immunol (2014) 0.92
CD8+ T cells specific for the androgen receptor are common in patients with prostate cancer and are able to lyse prostate tumor cells. Cancer Immunol Immunother (2011) 0.84
Immunization with a prostate cancer xenoantigen elicits a xenoantigen epitope-specific T-cell response. Oncoimmunology (2012) 0.83
Human Tumor Antigens and Cancer Immunotherapy. Biomed Res Int (2015) 0.81
An artificial PAP gene breaks self-tolerance and promotes tumor regression in the TRAMP model for prostate carcinoma. Mol Ther (2011) 0.80
Tumor-associated antigens for specific immunotherapy of prostate cancer. Cancers (Basel) (2012) 0.80
DNA vaccines encoding altered peptide ligands for SSX2 enhance epitope-specific CD8+ T-cell immune responses. Vaccine (2014) 0.79
Immunotherapy for prostate cancer: False promises or true hope? Cancer (2016) 0.78
Antitumor vaccination of prostate cancer patients elicits PD-1/PD-L1 regulated antigen-specific immune responses. Oncoimmunology (2016) 0.76
Mini-intronic plasmid vaccination elicits tolerant LAG3(+) CD8(+) T cells and inferior antitumor responses. Oncoimmunology (2016) 0.75
Sipuleucel-T: immunotherapy for advanced prostate cancer. Open Access J Urol (2011) 0.75
Presence of antigen-specific somatic allelic mutations and splice variants do not predict for immunological response to genetic vaccination. J Immunother Cancer (2013) 0.75
SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics (1999) 14.15
Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A (2002) 8.72
Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol (1994) 8.16
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol (2006) 5.72
AN " ACID " PHOSPHATASE OCCURRING IN THE SERUM OF PATIENTS WITH METASTASIZING CARCINOMA OF THE PROSTATE GLAND. J Clin Invest (1938) 5.00
Peptides naturally presented by MHC class I molecules. Annu Rev Immunol (1993) 4.66
Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer (2009) 4.12
Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J Clin Oncol (2009) 3.51
Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol (2000) 3.48
Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin Invest (2001) 2.11
Molecular characterization of defective antigen processing in human prostate cancer. J Natl Cancer Inst (1995) 1.90
Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res (2000) 1.81
Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: implications for immunotherapy of prostate cancer. J Immunol (1997) 1.80
Demonstration of the prostatic origin of metastases: an immunohistochemical method for formalin-fixed embedded tissue. Cancer (1978) 1.71
Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J Immunol (2001) 1.46
Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP). Vaccine (2005) 1.23
Plasmid DNA vaccine encoding prostatic acid phosphatase is effective in eliciting autologous antigen-specific CD8+ T cells. Cancer Immunol Immunother (2006) 1.20
DNA typing for HLA class I alleles: I. Subsets of HLA-A2 and of -A28. Hum Immunol (1992) 1.10
Induction of prostate tumor-specific CD8+ cytotoxic T-lymphocytes in vitro using antigen-presenting cells pulsed with prostatic acid phosphatase peptide. Prostate (1998) 1.07
Comparative analysis of prostate-specific membrane antigen (PSMA) versus a prostate-specific membrane antigen-like gene. Prostate (2004) 1.02
Recognition by HLA-A2-restricted cytotoxic T lymphocytes of endogenously generated and exogenously provided synthetic peptide analogues of the influenza A virus matrix protein. Hum Immunol (1993) 0.91
Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy. Cancer Res (2005) 0.91
Prostatic acid phosphatase as a target molecule in specific immunotherapy for patients with nonprostate adenocarcinoma. J Immunother (2005) 0.90
Pilot study of an HLA-A2 peptide vaccine using flt3 ligand as a systemic vaccine adjuvant. J Clin Immunol (2003) 0.88
Resistance to lysis by cytotoxic T cells: a dominant effect in metastatic mouse prostate cancer cells. Cancer Res (2000) 0.87
Prostate-related antigen-derived new peptides having the capacity of inducing prostate cancer-reactive CTLs in HLA-A2+ prostate cancer patients. Oncol Rep (2004) 0.87
Peptide vaccines against cancer. Cancer Treat Res (2005) 0.82
Prostate cancer antigens and vaccines, preclinical developments. Cancer Chemother Biol Response Modif (2005) 0.79
An evaluation of the immunochemical measurement of prostatic acid phosphatase and prostatic specific antigen in carcinoma of the prostate. Eur Urol (1986) 0.78
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 22.96
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med (2003) 7.35
Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol (2010) 6.04
Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J Clin Oncol (2009) 3.51
Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Res (2009) 3.30
Spontaneous autoimmunity prevented by thymic expression of a single self-antigen. J Exp Med (2006) 3.20
A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res (2007) 2.71
Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother (2002) 2.65
Community-associated extended-spectrum β-lactamase-producing Escherichia coli infection in the United States. Clin Infect Dis (2012) 2.58
Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol (2002) 2.54
Transcriptome-wide studies of merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival. J Clin Oncol (2011) 2.52
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin Cancer Res (2011) 2.44
Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res (2009) 2.32
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOT. BMC Immunol (2005) 2.31
Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clin Cancer Res (2007) 2.20
Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma. Gastroenterology (2009) 2.04
Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol (2008) 2.01
Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients. Cancer Res (2010) 1.89
Contact precautions: more is not necessarily better. Infect Control Hosp Epidemiol (2014) 1.88
CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. Blood (2008) 1.81
A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". J Transl Med (2008) 1.77
A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther (2006) 1.74
Expression and immunotherapeutic targeting of the SSX family of cancer-testis antigens in prostate cancer. Cancer Res (2011) 1.66
Immunoediting of cancers may lead to epithelial to mesenchymal transition. J Immunol (2006) 1.65
TGFbeta/TNF(alpha)-mediated epithelial-mesenchymal transition generates breast cancer stem cells with a claudin-low phenotype. Cancer Res (2011) 1.65
HER-2/neu antigen loss and relapse of mammary carcinoma are actively induced by T cell-mediated anti-tumor immune responses. Eur J Immunol (2007) 1.60
GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1- bone marrow progenitor cells into myeloid-derived suppressor cells. Breast Cancer Res Treat (2009) 1.60
Precision and linearity targets for validation of an IFNgamma ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides. BMC Immunol (2008) 1.60
Tumor-infiltrating Foxp3-CD4+CD25+ T cells predict poor survival in renal cell carcinoma. Clin Cancer Res (2007) 1.59
Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer. J Proteome Res (2008) 1.59
Immuno-oncology biomarkers 2010 and beyond: perspectives from the iSBTc/SITC biomarker task force. J Transl Med (2010) 1.57
Tumor immunoediting and immunosculpting pathways to cancer progression. Semin Cancer Biol (2007) 1.55
IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice. J Immunol (2006) 1.53
Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity. Clin Cancer Res (2002) 1.51
The androgen receptor: a biologically relevant vaccine target for the treatment of prostate cancer. Cancer Immunol Immunother (2012) 1.50
Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors. Cancer Res (2007) 1.49
Neu antigen-negative variants can be generated after neu-specific antibody therapy in neu transgenic mice. Cancer Res (2004) 1.49
CD4 regulatory T cells in human cancer pathogenesis. Cancer Immunol Immunother (2006) 1.47
Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumors. Cancer Res (2008) 1.38
Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. J Transl Med (2009) 1.31
Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer. J Clin Oncol (2006) 1.31
TNM staging in colorectal cancer: T is for T cell and M is for memory. J Clin Oncol (2011) 1.30
Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer. J Immunol (2011) 1.28
Treatment failure of a TLR-7 agonist occurs due to self-regulation of acute inflammation and can be overcome by IL-10 blockade. J Immunol (2010) 1.26
VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC. Clin Cancer Res (2011) 1.25
Insulin-like growth factor-binding protein-2 is a target for the immunomodulation of breast cancer. Cancer Res (2008) 1.24
Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer. J Clin Oncol (2010) 1.24
Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP). Vaccine (2005) 1.23
Islet transplantation in type 1 diabetic patients using calcineurin inhibitor-free immunosuppressive protocols based on T-cell adhesion or costimulation blockade. Transplantation (2010) 1.23
SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade. Proc Natl Acad Sci U S A (2008) 1.22
The tumor antigen repertoire identified in tumor-bearing neu transgenic mice predicts human tumor antigens. Cancer Res (2006) 1.22
The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer. PLoS One (2013) 1.22
Immune promotion of epithelial-mesenchymal transition and generation of breast cancer stem cells. Cancer Res (2010) 1.21
The endogenous danger signal, crystalline uric acid, signals for enhanced antibody immunity. Blood (2007) 1.21
Plasmid DNA vaccine encoding prostatic acid phosphatase is effective in eliciting autologous antigen-specific CD8+ T cells. Cancer Immunol Immunother (2006) 1.20
Polysaccharide krestin is a novel TLR2 agonist that mediates inhibition of tumor growth via stimulation of CD8 T cells and NK cells. Clin Cancer Res (2010) 1.20
Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein--based vaccine. J Clin Oncol (2004) 1.19
Immunization of cancer patients with HER-2/neu-derived peptides demonstrating high-affinity binding to multiple class II alleles. Clin Cancer Res (2003) 1.19
Renal hemodynamic, inflammatory, and apoptotic responses to lipopolysaccharide in HO-1-/- mice. Am J Pathol (2007) 1.16
In vivo manipulation of dendritic cells to induce therapeutic immunity. Blood (2002) 1.16
Optimizing patient derived mesenchymal stem cells as virus carriers for a phase I clinical trial in ovarian cancer. J Transl Med (2013) 1.16
Identification of an autoantigen demonstrates a link between interstitial lung disease and a defect in central tolerance. Sci Transl Med (2009) 1.15
Level of HER-2/neu protein expression in breast cancer may affect the development of endogenous HER-2/neu-specific immunity. Mol Cancer Ther (2008) 1.15
Evaluation of known oncoantibodies, HER2, p53, and cyclin B1, in prediagnostic breast cancer sera. Cancer Prev Res (Phila) (2012) 1.15
Endogenous anti-HER2 antibodies block HER2 phosphorylation and signaling through extracellular signal-regulated kinase. Cancer Res (2005) 1.14
Rheumatoid arthritis and cardiovascular disease. Am Heart J (2013) 1.14
Chitosan-alginate 3D scaffolds as a mimic of the glioma tumor microenvironment. Biomaterials (2010) 1.14
Functional T cell responses to tumor antigens in breast cancer patients have a distinct phenotype and cytokine signature. J Immunol (2007) 1.14
Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy. J Clin Oncol (2007) 1.14
DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer. J Immunother (2010) 1.12
Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinoma. Cancer Immunol Immunother (2011) 1.11
Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockade. J Immunol (2012) 1.09
Inducible expression of a prostate cancer-testis antigen, SSX-2, following treatment with a DNA methylation inhibitor. Prostate (2007) 1.09
Diversity of antigen-specific responses induced in vivo with CTLA-4 blockade in prostate cancer patients. J Immunol (2012) 1.09
A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma. Cancer (2011) 1.08
Prostate cancer patients on androgen deprivation therapy develop persistent changes in adaptive immune responses. Hum Immunol (2010) 1.08
Clinical and microbiologic characteristics of cephalosporin-resistant Escherichia coli at three centers in the United States. Antimicrob Agents Chemother (2012) 1.07
Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcome. J Urol (2007) 1.07
Humoral epitope-spreading following immunization with a HER-2/neu peptide based vaccine in cancer patients. J Clin Immunol (2004) 1.07
Immunity and immune suppression in human ovarian cancer. Immunotherapy (2011) 1.07
The SSX family of cancer-testis antigens as target proteins for tumor therapy. Clin Dev Immunol (2010) 1.06
Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides. J Immunother (2007) 1.05
ELISpot for measuring human immune responses to vaccines. Expert Rev Vaccines (2011) 1.04
Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain. Cancer Res (2006) 1.04
LPS-induced murine systemic inflammation is driven by parenchymal cell activation and exclusively predicted by early MCP-1 plasma levels. Am J Pathol (2011) 1.04